Search jobs
14-Dec-2020
TYK2 Identified as a Key Genetic Mechanism of Critical Illness in Covid-19 and as an Important Potential Target for Therapy
Findings published in
Nature support scientific rationale for Sareum’s SDC-1801 development programme in Covid-19 and its recent grant award from UKRI
Cambridge, UK, 14 December 2020 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to note that a multi-centre analysis of DNA samples from patients with severe forms of Covid-19, including symptoms caused by the over-active inflammatory response (“cytokine storm”), has identified TYK2 as a key causative genetic mechanism and a potential target for therapy.